NCT02081495View on ClinicalTrials.gov

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Neoplasms
Interventions
DRUG

DOXIL/CAELYX reference product (Treatment A)

Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.

DRUG

DOXIL/CAELYX test product (Treatment B)

Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.

Trial Locations (6)

Unknown

Los Angeles

Brussels

Wilrijk

Edmonton

Barcelona

Madrid

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02081495 - A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter